8-K
filed January 9, 2023, 6:59 PM ET
ticker WGS
CIK 0001818331
earnings
confidence high
sentiment positive
materiality 0.70
GeneDx (formerly Sema4) eyes 37-40% revenue growth to ~$170-173M in 2022; guides 2023 rev $205-220M
GeneDx Holdings Corp.
2022-FY EPS reported
-$1.63
revenue$234,694,000
- Preliminary pro forma 2022 revenue $170-173M, up 37-40% YoY from $123.7M.
- Pro forma test result volume >180,000 (+23% YoY); adjusted gross margin 38-41% (up from 34%).
- 2023 guidance: revenue $205-220M; cash burn for continuing ops $95-110M; targeting profitability in 2025.
- Name changed to GeneDx Holdings Corp.; common stock begins trading under WGS on Jan 10, 2023.
- CEO highlights combination of GeneDx and Centrellis platforms to accelerate precision medicine.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
GeneDx Holdings Corp. reported 2022 results: revenue $170-173 million.
- Period
- 2022
- Revenue
- $170-173 million
- Result
- preliminary results
Exact text from the filing
Preliminary 2022 Financial Results (Unaudited) Excluding revenues and costs from the previously announced exited reproductive health and somatic tumor testing businesses, management expects GeneDx to: • Generate pro forma revenues between $170-173 million in 2022, an approximate 37-40% increase from pro forma $123.7 million in 2021;
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
GeneDx Holdings Corp. reported full year 2023 results: revenue $205-220 million. Guidance initiated.
- Period
- full year 2023
- Revenue
- $205-220 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
2023 Guidance (Unaudited) The continuing operations of GeneDx, excluding revenues and costs from exited business activities, are expected to: • Generate revenues between $205-220 million for full year 2023;
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
GeneDx Holdings Corp.: Company changed name from Sema4 Holdings Corp. to GeneDx Holdings Corp. via a certificate of amendment to its certificate of incorporation, effective January 9, 2023 (effective 2023-01-09).
- Change
- charter amendment
- Effective
- 2023-01-09
Exact text from the filing
Effective as of January 9, 2023, GeneDx Holdings Corp. (the “ Company ”) changed its name from “Sema4 Holdings Corp.” to “GeneDx Holdings Corp.” (the “ Name Change ”) pursuant to a certificate of amendment to its certificate of incorporation (the “ Certificate of Amendment ”).
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
GeneDx Holdings Corp.: Board adopted amended and restated bylaws effective January 9, 2023, incorporating updates for name change, universal proxy rules, DGCL changes, and other revisions (effective 2023-01-09).
- Change
- bylaw amendment
- Effective
- 2023-01-09
Exact text from the filing
the Board also approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), effective as of January 9, 2023, in connection with the Name Change as well as the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the DGCL, and a periodic review of the bylaws of the Company.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.